Selected research
Industry Research
Haemophilus Influenzae Type B Vaccine Industry Research Report 2026
Market perspective
The global Haemophilus Influenzae Type B Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Haemophilus Influenzae Type B Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Haemophilus Influenzae Type B Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Haemophilus Influenzae Type B Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Haemophilus Influenzae Type B Vaccine include Takeda Pharmaceuticals Company, Sanofi, Novartis, Merck, Lanzhou Institute of Biologica, GlaxoSmithKline, Walvax Biotechnology and Immunize BC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Haemophilus Influenzae Type B Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Haemophilus Influenzae Type B Vaccine Market by Company
Takeda Pharmaceuticals Company
Sanofi
Novartis
Merck
Lanzhou Institute of Biologica
GlaxoSmithKline
Walvax Biotechnology
Immunize BC
Haemophilus Influenzae Type B Vaccine Segment by Type
Liquid Combination HIB
Liquid Monovalent HIB
Lyophilized Combination HIB
Lyophilized Monovalent HIB
Haemophilus Influenzae Type B Vaccine Segment by Application
Pharmaceutical and Biotechnology Companies
Hospital
Research Institutions
Academic Institutions
Other
Haemophilus Influenzae Type B Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Haemophilus Influenzae Type B Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Haemophilus Influenzae Type B Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Haemophilus Influenzae Type B Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Haemophilus Influenzae Type B Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Haemophilus Influenzae Type B Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Haemophilus Influenzae Type B Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liquid Combination HIB
- Liquid Monovalent HIB
- Lyophilized Combination HIB
- Lyophilized Monovalent HIB
Applications
- Pharmaceutical and Biotechnology Companies
- Hospital
- Research Institutions
- Academic Institutions
- Other
Companies covered
- Takeda Pharmaceuticals Company
- Sanofi
- Novartis
- Merck
- Lanzhou Institute of Biologica
- GlaxoSmithKline
- Walvax Biotechnology
- Immunize BC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Haemophilus Influenzae Type B Vaccine Market Size (2021-2032)
- 2.2.2 Global Haemophilus Influenzae Type B Vaccine Sales (2021-2032)
- 2.2.3 Global Haemophilus Influenzae Type B Vaccine Market Average Price (2021-2032)
- 2.3 Haemophilus Influenzae Type B Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Liquid Combination HIB
- 2.3.3 Liquid Monovalent HIB
- 2.3.4 Lyophilized Combination HIB
- 2.3.5 Lyophilized Monovalent HIB
- 2.4 Haemophilus Influenzae Type B Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pharmaceutical and Biotechnology Companies
- 2.4.3 Hospital
- 2.4.4 Research Institutions
- 2.4.5 Academic Institutions
- 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Haemophilus Influenzae Type B Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Haemophilus Influenzae Type B Vaccine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Haemophilus Influenzae Type B Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Haemophilus Influenzae Type B Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Haemophilus Influenzae Type B Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Haemophilus Influenzae Type B Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Haemophilus Influenzae Type B Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Haemophilus Influenzae Type B Vaccine, Established Date
- 3.9 Global Haemophilus Influenzae Type B Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda Pharmaceuticals Company
- 4.1.1 Takeda Pharmaceuticals Company Company Information
- 4.1.2 Takeda Pharmaceuticals Company Business Overview
- 4.1.3 Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Pharmaceuticals Company Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.1.5 Takeda Pharmaceuticals Company Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Merck
- 4.4.1 Merck Company Information
- 4.4.2 Merck Business Overview
- 4.4.3 Merck Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.4.5 Merck Recent Developments
- 4.5 Lanzhou Institute of Biologica
- 4.5.1 Lanzhou Institute of Biologica Company Information
- 4.5.2 Lanzhou Institute of Biologica Business Overview
- 4.5.3 Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lanzhou Institute of Biologica Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.5.5 Lanzhou Institute of Biologica Recent Developments
- 4.6 GlaxoSmithKline
- 4.6.1 GlaxoSmithKline Company Information
- 4.6.2 GlaxoSmithKline Business Overview
- 4.6.3 GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.6.5 GlaxoSmithKline Recent Developments
- 4.7 Walvax Biotechnology
- 4.7.1 Walvax Biotechnology Company Information
- 4.7.2 Walvax Biotechnology Business Overview
- 4.7.3 Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Walvax Biotechnology Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.7.5 Walvax Biotechnology Recent Developments
- 4.8 Immunize BC
- 4.8.1 Immunize BC Company Information
- 4.8.2 Immunize BC Business Overview
- 4.8.3 Immunize BC Haemophilus Influenzae Type B Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Immunize BC Haemophilus Influenzae Type B Vaccine Product Portfolio
- 4.8.5 Immunize BC Recent Developments
5 Global Haemophilus Influenzae Type B Vaccine Market Scenario by Region
- 5.1 Global Haemophilus Influenzae Type B Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Haemophilus Influenzae Type B Vaccine Sales by Region: 2027-2032
- 5.3 Global Haemophilus Influenzae Type B Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Haemophilus Influenzae Type B Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Haemophilus Influenzae Type B Vaccine Revenue by Region: 2027-2032
- 5.4 North America Haemophilus Influenzae Type B Vaccine Market Facts & Figures by Country
- 5.4.1 North America Haemophilus Influenzae Type B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Haemophilus Influenzae Type B Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Haemophilus Influenzae Type B Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Haemophilus Influenzae Type B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Haemophilus Influenzae Type B Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Haemophilus Influenzae Type B Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Haemophilus Influenzae Type B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Haemophilus Influenzae Type B Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Haemophilus Influenzae Type B Vaccine Market Facts & Figures by Country
- 5.7.1 South America Haemophilus Influenzae Type B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Haemophilus Influenzae Type B Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Haemophilus Influenzae Type B Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Haemophilus Influenzae Type B Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Haemophilus Influenzae Type B Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Haemophilus Influenzae Type B Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Haemophilus Influenzae Type B Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Haemophilus Influenzae Type B Vaccine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Haemophilus Influenzae Type B Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Haemophilus Influenzae Type B Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Haemophilus Influenzae Type B Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Haemophilus Influenzae Type B Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Haemophilus Influenzae Type B Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Haemophilus Influenzae Type B Vaccine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Haemophilus Influenzae Type B Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Haemophilus Influenzae Type B Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Haemophilus Influenzae Type B Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Haemophilus Influenzae Type B Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Haemophilus Influenzae Type B Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Haemophilus Influenzae Type B Vaccine Value Chain Analysis
- 8.1.1 Haemophilus Influenzae Type B Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Haemophilus Influenzae Type B Vaccine Production Mode & Process
- 8.2 Haemophilus Influenzae Type B Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Haemophilus Influenzae Type B Vaccine Distributors
- 8.2.3 Haemophilus Influenzae Type B Vaccine Customers
9 Global Haemophilus Influenzae Type B Vaccine Analyzing Market Dynamics
- 9.1 Haemophilus Influenzae Type B Vaccine Industry Trends
- 9.2 Haemophilus Influenzae Type B Vaccine Industry Drivers
- 9.3 Haemophilus Influenzae Type B Vaccine Industry Opportunities and Challenges
- 9.4 Haemophilus Influenzae Type B Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst